Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a trial of 5 fraction SBRT combined with androgen deprivation therapy for patients
with localized high-risk or unfavorable intermediate risk prostate cancer